Interpace Biosciences, Inc. (IDXG)

Market Cap	52.63M +911.4%
Revenue (ttm)	36.25M -17.5%
Net Income	23.65M +266.7%
EPS	0.86 -36.5%
Shares Out	27.70M
PE Ratio	2.18
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,365
Average Volume	6,874
Open	2.000
Previous Close	2.000
Day's Range	1.900 - 2.050
52-Week Range	0.697 - 2.400
Beta	0.65
RSI	53.07
Earnings Date	Aug 10, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and cha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 102
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2025, Interpace Biosciences's revenue was $38.73 million, a decrease of -17.47% compared to the previous year's $46.93 million. Earnings were $24.58 million, an increase of 293.96%.